Clinical Outcomes of Hepatitis C Treated with Pegylated Interferon and Ribavirin via Telemedicine Consultation in Northern California
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Patients in rural communities are less likely to receive treatment for their hepatitis C (HCV) infection. Telemedicine (TM) consultation can close the gap of access to specialists in remote and under-served areas.
To determine treatment response and side-effect profiles among HCV patients treated with pegylated interferon and ribavirin via TM consultation in different rural locations in Northern California compared with patients treated in traditional hepatology office visits.
We performed a retrospective analysis of 80 HCV patients treated at different TM sites (TM, n = 40) and at the University of California Davis Hepatology Clinic (HC, n = 40) between 2006 and 2010, comparing baseline characteristics and clinical outcomes.
At baseline, response to therapy was similar for patients in both groups. Sustained virological response (SVR) was similar in both groups (TM: 55 vs. HC: 43 %; p = 0.36), and a higher proportion of patients treated via telemedicine completed treatment (TM: 78 vs. HC: 53 %; p = 0.03). TM patients had many more visits per week of therapy (TM: 0.61 vs. HC: 0.07; p < 0.001). Neutropenia, GI side effects, fatigue, depression, weight loss, insomnia, and skin rash were similar in both groups. For HC patients incidence of anemia was significantly higher (53 %) than for the TM group (25 %; p = 0.02).
The two groups had equivalent SVR. For the TM group therapy completion was superior and incidence of anemia was lower. This initial study suggests that, as a group, patients with HCV, can be safely and effectively treated via telemedicine.
- Ly, KN, Xing, J, Klevens, RM (2012) The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 156: pp. 271-278 CrossRef
- Daniels D. Surveillance for acute viral hepatitis—United States, 2007. Source: morbidity and mortality weekly report. CDC Surveillance Summ [1546-0738]. 2009;58:1–27.
- Wise, M, Bialek, S, Finelli, L, Bell, BP, Sorvillo, F (2008) Changing trends in hepatitis C-related mortality in the United States, 1995–2004. Hepatology 47: pp. 1128-1135 CrossRef
- Armstrong, GL, Wasley, A, Simard, EP (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: pp. 705-714 CrossRef
- Verna, EC, Brown, RS (2006) Hepatitis C and liver transplantation. Clin Liver Dis 10: pp. 919 CrossRef
- Freeman, RB, Steffick, DE, Guidinger, MK, Farmer, DG, Berg, CL, Merion, RM (2008) Liver and intestine transplantation in the United States, 1997–2006. Am J Transplant 8: pp. 958-976 CrossRef
- Leigh, JP, Bowlus, CL, Leistikow, BN, Schenker, M (2001) Cost of hepatitis C. Arch Intern Med 161: pp. 22-31 CrossRef
- Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 47: pp. 1-39
- Rocca, LG, Yawn, BP, Wollan, P, Kim, WR (2004) Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2: pp. 116-124 CrossRef
- Simin, M, Brok, J, Stimac, D, Gluud, C, Gluud, LL (2007) Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 25: pp. 1153-1162 CrossRef
- Veldt, BJ, Heathcote, EJ, Wedemeyer, H (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147: pp. 677-684 CrossRef
- Kasahara, A, Tanaka, H, Okanoue, T (2004) Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver related death. J Viral Hepat 11: pp. 148-156 CrossRef
- Poodard, F, McCone, J, Bacon, B (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: pp. 1195-1206 CrossRef
- Bacon, BR, Gordon, SC, Lawitz, E (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: pp. 1207-1217 CrossRef
- Yawn, BP, Wollan, P, Gazzuola, L, Kim, WR (2002) Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract 51: pp. 135-140
- Rossaro, L, Aoki, C, Yuk, J, Prosser, C, Goforth, J, Martinez, F (2008) The evaluation of patients with hepatitis C living in rural California via telemedicine. Telemed e-Health 14: pp. 1127-1129 CrossRef
- Arora, S, Thornton, K, Murata, G (2011) Outcomes of treatment for hepatitis C virus infection by primary care providers. N Eng J Med 364: pp. 2199-2207 CrossRef
- Rossaro, L, Tran, TP, Cole, SL, Nesbitt, TS (2003) Telemedicine: improving access to care of hepatitis C. Pract Gastroenterol 17: pp. 21-22
- Torruellas C, Rossaro CC, Li C-S, Rossaro L. The use of telemedicine for the management of hepatitis C & the California telehealth network, advances in telemedicine. In: Graschew G, ed. Applications in Various Medical Disciplines and Geographical Regions. InTech; 2011. ISBN: 978-953-307-161-9. doi:10.5772/14451, modified).
- Clinical Outcomes of Hepatitis C Treated with Pegylated Interferon and Ribavirin via Telemedicine Consultation in Northern California
Digestive Diseases and Sciences
Volume 58, Issue 12 , pp 3620-3625
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Hepatitis C
- Medically under-served areas
- Rural communities
- Industry Sectors